Syn-Ake

A synthetic tripeptide designed as a mimetic of waglerin-1, a temple-viper venom peptide toxin — marketed as "topical Botox" on the idea of mild local muscle relaxation smoothing expression lines. A staple of K-beauty formulations.

SYN-AKE is a synthetic tripeptide designed to imitate a component of temple viper venom. The supplier-proposed mechanism is that it blocks the receptor muscles use to receive nerve signals, so blocking it in facial muscles would relax them and soften expression lines — proposed, not demonstrated: the human study measured wrinkle geometry, not receptor blockade or muscle relaxation, and target engagement in people has never been shown. The obvious problem sits between the mechanism and the skin: botulinum toxin is injected into muscle precisely because it cannot get there any other way, and a peptide applied to the surface has to cross skin and reach muscle to do what is claimed.

It is designed as a waglerin-1 mimetic, but clinically meaningful delivery through intact skin to muscle has not been established. Supporting studies are small and largely supplier-funded, measuring modest wrinkle metrics.

• LIMITED and largely manufacturer-supported. Small studies report reductions in wrinkle depth over weeks.
• NONE SHOWN for the comparison the marketing invites: no trial establishes any effect comparable to injected botulinum toxin, and the mechanisms are not equivalent even in principle at the surface.
• Whether meaningful amounts reach facial muscle after topical application is the unresolved question, and it is not a minor technicality — it is the entire claim.
• Any measured smoothing in a cosmetic trial may reflect hydration and the formulation base rather than neuromuscular effect, which cosmetic study designs typically cannot separate.
• It is a cosmetic ingredient and is not subject to efficacy review before sale.

Applied topically. Skin penetration to the depth of facial muscle is not established. Concentration in finished products varies and is often undisclosed. Note that FDA does not approve ordinary cosmetics or verify their safety before marketing, so the ingredient's category is not a safety status — systemic toxicity has not emerged from the small topical study, but safety evidence is limited and formulation-specific, and irritation or allergy remains possible.

Essentially cosmetic-grade: irritation potential and expectation mismatch with actual Botox — which it is not. Included here so the name resolves; nothing about it belongs in an injection conversation.

• Anyone buying it as a substitute for an injectable treatment, which is a comparison no evidence supports
• Anyone with a known sensitivity to the formulation

• Generally well tolerated alongside other topicals.
• Nothing established at drug-interaction level — it is a cosmetic ingredient.

• Photographs under consistent lighting.
• Irritation, which is uncommon but possible with any leave-on product.
• Realistic expectation, which is the main thing at risk here — this is marketed against a comparison it has never been tested against.

No withdrawal and no rebound. Any effect fades over weeks. Given the modest and uncertain effect size, there may be nothing perceptible to notice on stopping.

US: cosmetic ingredient — not subject to FDA drug preapproval, but cosmetics remain regulated under federal cosmetics law.

Papers about this compound, not proof of the claims above. A title says what was studied, which is sometimes a negative result or a different question entirely.

• The effect of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone on skin biomarkers, wrinkles and skin texture: Ex vivo and clinical studies
  Int J Cosmet Sci, 2026
• Anti-aging activity of Syn-Ake peptide by in silico approaches and in vitro tests
  J Biomol Struct Dyn, 2024

• Immobilization with atrophy induces de novo expression of neuronal nicotinic α7 acetylcholine receptors in muscle contributing to neurotransmissionAnesthesiology · 2014
• The effect of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone on skin biomarkers, wrinkles and skin texture: Ex vivo and clinical studiesInt J Cosmet Sci · 2026
• Waglerin-1 inhibits GABA(A) current of neurons in the nucleus accumbens of neonatal ratsBrain Res · 1999
• Waglerin-1 selectively blocks the epsilon form of the muscle nicotinic acetylcholine receptorJ Pharmacol Exp Ther · 1999
• Protein engineering of venom toxins by synthetic approach and NMR dynamic simulation: status of basic amino acid residues in waglerin IBiochem Biophys Res Commun · 1996
• A study on the cause of death due to waglerin-I, a toxin from Trimeresurus wagleriToxicon · 1995
• De Novo Assembly of Venom Gland Transcriptome of Tropidolaemus wagleri (Temple Pit Viper, Malaysia) and Insights into the Origin of Its Major Toxin, WaglerinToxins (Basel) · 2023
• Structure-function studies of waglerin I, a lethal peptide from the venom of Wagler's pit viper, Trimeresurus wagleriToxicon · 1995
• Waglerin-1 modulates gamma-aminobutyric acid activated current of murine hypothalamic neuronsJ Pharmacol Exp Ther · 1997
• Binding of Ni2+ and Cu2+ ions to peptides with a Cys-His motifDalton Trans · 2008
• Determination of three-dimensional solution structure of waglerin I, a toxin from Trimeresurus wagleri, using 2D-NMR and molecular dynamics simulationBiochim Biophys Acta · 1996
• Effects of waglerin-I on neuromuscular transmission of mouse nerve-muscle preparationsToxicon · 1995